GlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by Credit Suisse Group Analysts

GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,600 ($20.91) target price by stock analysts at Credit Suisse Group in a report released on Thursday. The firm presently has a “neutral” rating on the stock. Credit Suisse Group’s price target suggests a potential upside of 2.25% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Barclays lowered GlaxoSmithKline to an “equal weight” rating and decreased their target price for the stock from GBX 1,750 ($22.87) to GBX 1,600 ($20.91) in a research report on Tuesday, December 4th. Jefferies Financial Group boosted their target price on GlaxoSmithKline from GBX 1,725 ($22.54) to GBX 1,750 ($22.87) and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Shore Capital lowered GlaxoSmithKline to a “hold” rating in a research report on Friday, January 18th. Finally, Deutsche Bank reissued a “hold” rating and issued a GBX 1,525 ($19.93) target price on shares of GlaxoSmithKline in a research report on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 1,520.93 ($19.87).

Shares of LON:GSK opened at GBX 1,564.80 ($20.45) on Thursday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($16.14) and a fifty-two week high of GBX 1,724.50 ($22.53).

In other GlaxoSmithKline news, insider Jesse Goodman purchased 845 shares of GlaxoSmithKline stock in a transaction dated Wednesday, February 6th. The stock was purchased at an average price of GBX 1,964 ($25.66) per share, with a total value of £16,595.80 ($21,685.35). Insiders have bought a total of 861 shares of company stock valued at $1,683,724 in the last ninety days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Retained Earnings

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply